Person:
Vercauteren, Marcel

Email Address
marcel.vercauteren@uza.be
Birth Date
1990-01-01
Organizational Units
Organizational Unit
Abdominal and Paediatric Surgery
Antwerp Surgical Training, Anatomy and Research Centre (ASTARC) is a multidisciplinary research team that incorporates the fundamental, clinical and translational research activities of 11 research laboratories of the Faculty of Medicine and Health Sciences at the University of Antwerp.
Organizational Unit
Anaesthesiology
Aim of the laboratory : diagnosis of Malignant Hyperthermia (MH) susceptibility by means of in vitro contracture testing according to the protocol of the European MH Group (www.emhg.org); detection of associated structural myopathies; clinical counselling concerning MH-susceptibility; genetic counselling.
Organizational Unit
Organizational Unit
Organizational Unit
Job Title
Head of Anaesthesiology
Last Name
Vercauteren
First Name
Marcel

Search Results

Now showing 1 - 6 of 6
  • Publication
    TestArticle1
    Vercauteren, Marcel ; Abdominal and Paediatric Surgery ; Eens, Marcel ; Medicine and Health Sciences ; De Wael, Karolien ; Medicine and Health Sciences ; Abdominal and Paediatric Surgery ; Anaesthesiology
  • Publication
    TestTheses2
    (2018-05-17) Medicine and Health Sciences ; Abdominal and Paediatric Surgery ; Eens, Marcel ; Vercauteren, Marcel ; De Wael, Karolien ; Abdominal and Paediatric Surgery
  • Publication
    TestTheses1
    (2018-05-17) Eens, M. ; Vercauteren, Marcel ; De Wael, K. ; Anaesthesiology ; Abdominal and Paediatric Surgery
  • Publication
    TestBook1
    (2018-05-17) Eens, Marc ; Vercauteren, Marcel ; De Wael, Karolien ; Anaesthesiology ; Abdominal and Paediatric Surgery
  • Publication
    TestBook3
    (2018-05-17) Vercauteren, Marcel ; De Wael, Karolien ; Abdominal and Paediatric Surgery ; Anaesthesiology
  • Publication
    Dengue Human Infection Models Supporting Drug Development
    (2014-06-15) Plain text author ; Plain text author 2 ; Eens, Marcel ; Vercauteren, Marcel ; Simmons, Cameron
    Dengue is a arboviral infection that represents a major global health burden. There is an unmet need for effective dengue therapeutics to reduce symptoms, duration of illness and incidence of severe complications. Here, we consider the merits of a dengue human infection model (DHIM) for drug development. A DHIM could allow experimentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using smaller sample sizes than trials that recruited patients with dengue in an endemic country. In addition, the DHIM would assist the conduct of intensive pharmacokinetic and basic research investigations and aid in determining optimal drug dosage. Furthermore, a DHIM could help establish proof of concept that chemoprophylaxis against dengue is feasible. The key challenge in developing the DHIM for drug development is to ensure the model reliably replicates the typical clinical and laboratory features of naturally acquired, symptomatic dengue.